<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/955C55E8-783E-4842-BB2C-2D275A3CAF82"><gtr:id>955C55E8-783E-4842-BB2C-2D275A3CAF82</gtr:id><gtr:name>University of Portsmouth</gtr:name><gtr:department>Sch of Pharmacy &amp; Biomedical Sciences</gtr:department><gtr:address><gtr:line1>University House</gtr:line1><gtr:line2>Winston Churchill Avenue</gtr:line2><gtr:line4>Portsmouth</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>PO1 2UP</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/955C55E8-783E-4842-BB2C-2D275A3CAF82"><gtr:id>955C55E8-783E-4842-BB2C-2D275A3CAF82</gtr:id><gtr:name>University of Portsmouth</gtr:name><gtr:address><gtr:line1>University House</gtr:line1><gtr:line2>Winston Churchill Avenue</gtr:line2><gtr:line4>Portsmouth</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>PO1 2UP</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:line4>Swindon</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SN2 1ET</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>CO_FUNDER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7F875EC7-9F4B-4CA9-A3BD-8574B0C6C19D"><gtr:id>7F875EC7-9F4B-4CA9-A3BD-8574B0C6C19D</gtr:id><gtr:firstName>Geoffrey</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Pilkington</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7E85777F-A337-4EB7-B632-DC92CBB56615"><gtr:id>7E85777F-A337-4EB7-B632-DC92CBB56615</gtr:id><gtr:firstName>J</gtr:firstName><gtr:surname>Tsibouklis</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B20783E0-0CD3-4796-9362-FA6451D38FB4"><gtr:id>B20783E0-0CD3-4796-9362-FA6451D38FB4</gtr:id><gtr:firstName>Dariusz</gtr:firstName><gtr:surname>Gorecki</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2E7941B7-B549-4503-B97A-A68633E53FDE"><gtr:id>2E7941B7-B549-4503-B97A-A68633E53FDE</gtr:id><gtr:firstName>Eugen</gtr:firstName><gtr:surname>Barbu</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FF011865%2F1"><gtr:id>7F7E5175-59B7-434D-AFD0-F6C601A0D88A</gtr:id><gtr:title>Nanoparticulate chemotherapeutic drug transporters for delivery across the blood-brain barrier</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/F011865/1</gtr:grantReference><gtr:abstractText>This project is aimed towards the preparation and evaluation of polymer-based nanoparticulate vehicles that have an increased lifetime in the circulatory system and facilitate drug delivery (through the blood-brain barrier) to the brain, via specific transport mechanisms. The study will be centred on biodegradable nanoparticles that possess moderate-hydrophilic surfaces and that can be loaded with chemotherapeutic agents known to be active in a range of the central nervous system (CNS) diseases, but normally limited by the blood-brain barrier in reaching their site of action. This work will generate a range of well-characterised nano-formulations whose performance and toxicity will be evaluated both in vitro and in vivo. The results generated by this study are expected to bring a significant contribution to the process of developing effective drug targeting technologies.</gtr:abstractText><gtr:technicalSummary>This project is aimed towards the formulation and evaluation of new polymeric nano-carriers that can overcome the reticulo-endothelial system (RES) phagocytosis and facilitate drug delivery through the blood-brain barrier (BBB) via nanoparticle-mediated transport. The study will be centred on biodegradable nano-sized structures that possess moderate-hydrophilic surfaces and can be loaded with chemotherapeutic agents known to be active in a range of central nervous system (CNS) diseases, but are normally limited by the BBB in reaching the site of action. This work will generate a range of well-characterised nano-formulations whose performance and toxicity will be evaluated both in vitro and in vivo. The results generated by this study are expected to bring a significant contribution to the process of developing effective BBB drug targeting technologies.</gtr:technicalSummary><gtr:fund><gtr:end>2011-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2008-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>449616</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Biomaterials for aging populations 1st UK-China Summer School. Sichuan University,  Chengdu, Sichuan Province, China</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2E788390-0C09-4451-BDCA-EEF287D795E1</gtr:id><gtr:impact>discussions with potential collaborators

-</gtr:impact><gtr:outcomeId>5460bc076341d0.94859808</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UKICRS Symposium, Kings College London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7EA4B77C-55CB-45E3-8F3E-E602E80FCD8C</gtr:id><gtr:impact>-</gtr:impact><gtr:outcomeId>5460bd0b4ef6a7.96159688</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Focus on Health - Brain</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E1614F46-3E08-4800-9543-D2CE74199E97</gtr:id><gtr:impact>discussions

increase public awareness</gtr:impact><gtr:outcomeId>5460c1dc6890b7.84258932</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>24th European Conference on Biomaterials, Dublin, Ireland</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7779BB93-A6E4-4905-A776-414B1EF31465</gtr:id><gtr:impact>.</gtr:impact><gtr:outcomeId>5460be717f3ed1.68552178</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Emerging Pharmaceutical Scientists, AstraZeneca, Loughborough, UK</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>32C9AB27-2EF2-4036-A70A-552274935017</gtr:id><gtr:impact>.</gtr:impact><gtr:outcomeId>5460bf1f8cfab3.69278696</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>151877</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>3D-all-human blood-brain barrier model in evaluating nanoparticle-facilitated drug delivery systems</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>Dr Hadwen Trust (DHT)</gtr:fundingOrg><gtr:id>948A47F1-7F2B-4EE4-B234-21B8B7126CCE</gtr:id><gtr:outcomeId>5460c0c335d553.92241396</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>423227</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Interreg : European Territorial Co-operation</gtr:department><gtr:description>Peptide Research Network of Excellence</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>EECE32DC-EAC5-4E51-A07D-8B338643E283</gtr:id><gtr:outcomeId>5460c049cbecf3.25607261</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The invention relates to a saccharide or polysaccharide substituted at one or more -OH functionalities with an alkyl glycerol; wherein the polysaccharide is selected from chitosan, chitin, polyglucosamine and derivatives and combinations thereof, and wherein the saccharide is selected from glucosamine and derivatives thereof. Particles formed from these saccharides or polysaccharides, and methods of preparation of the particles are also disclosed.</gtr:description><gtr:grantRef>BB/F011865/1</gtr:grantRef><gtr:id>C9E117FA-544D-42EA-BDA2-4E481E2427BA</gtr:id><gtr:impact>-</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>5460b5bc73e617.66573033</gtr:outcomeId><gtr:patentId>WO 2011104134 A1</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Saccharide derivatives</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>This project was aimed towards the preparation and evaluation of polymer-based nanoparticulate vehicles that can permeate through the blood-brain barrier and facilitate drug delivery to the brain. The study was centred on biocompatible nanoparticles that can be loaded with fluorescent markers and chemotherapeutic agents known to be active in a range of diseases of the central nervous system, but their transport is prevented by the blood-brain barrier. This work generated a range of well-characterised nanomaterials that show high potential for delivering drugs into the brain.</gtr:description><gtr:exploitationPathways>The results generated by this study are expected to contribute towards the development of effective technologies for the delivery of therapeutic compounds to the brain.</gtr:exploitationPathways><gtr:id>C2554A48-EF10-42E9-9F55-51F20B442AD9</gtr:id><gtr:outcomeId>r-2242099998.744297577825a20</gtr:outcomeId><gtr:sectors><gtr:sector>Chemicals,Education,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>67923CBA-020F-4AC6-90BC-0E74C212BC81</gtr:id><gtr:title>Alkylglyceryl chitosan nanoparticles for drug delivery across the blood-brain barrier</gtr:title><gtr:parentPublicationTitle>Drug Discovery Today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/334c1bd0fb6e6936d4aba80241e19511"><gtr:id>334c1bd0fb6e6936d4aba80241e19511</gtr:id><gtr:otherNames>Moln?r ?</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>doi_53d08e08e3ed875c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F693B25-7556-4B06-A6E0-1A69E1655BA2</gtr:id><gtr:title>Nanoparticulate carriers for drug delivery to the brain</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd7934cc4cde4044537ef60bec881998"><gtr:id>fd7934cc4cde4044537ef60bec881998</gtr:id><gtr:otherNames>Molnar, E.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>5460b22b6e4a38.09098871</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA3F8572-CEB7-458B-937E-15AF0F408EA8</gtr:id><gtr:title>Toward drug delivery into the brain: synthesis, characterization, and preliminary in vitro assessment of alkylglyceryl-functionalized chitosan nanoparticles.</gtr:title><gtr:parentPublicationTitle>Biomacromolecules</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/96e43fe3ab77352db7886a85b9ddb0c9"><gtr:id>96e43fe3ab77352db7886a85b9ddb0c9</gtr:id><gtr:otherNames>Moln?r E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1525-7797</gtr:issn><gtr:outcomeId>pm_5435ad55ad56ae96f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BBACE75-F3B6-4EAB-8065-904087C8D871</gtr:id><gtr:title>In vitro assessment of alkylglyceryl-functionalized chitosan nanoparticles as permeating vectors for the blood-brain barrier.</gtr:title><gtr:parentPublicationTitle>Biomacromolecules</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d72fb53baea4473c59be25833bb45d8"><gtr:id>3d72fb53baea4473c59be25833bb45d8</gtr:id><gtr:otherNames>Lien CF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1525-7797</gtr:issn><gtr:outcomeId>pm_5435ad55ad55ee7b9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A53EF401-F372-4BBC-A142-923CFCAE1205</gtr:id><gtr:title>The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier.</gtr:title><gtr:parentPublicationTitle>Expert opinion on drug delivery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b2abde98bd7b386a589a797cc2602000"><gtr:id>b2abde98bd7b386a589a797cc2602000</gtr:id><gtr:otherNames>Barbu E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1742-5247</gtr:issn><gtr:outcomeId>pm_53cbf9cbf9cced7fd</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/F011865/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>